Alnylam announces approval of GIVLAARI by US FDA

This article was originally published here

AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of

The post Alnylam announces approval of GIVLAARI by US FDA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply